Physician profile
Mirei Malave
NPI 1356782445
$1,557.26
in general payments reported to CMS, 2019-2025
13 companies · $105 in 2025
The $105 reported for 2025 was less than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $216 · 2023: $538 · 2024: $699 · 2025: $105.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,341.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,341.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $377.00 | 2023-2025 | |
| Abbvie INC. | $372.18 | 2022-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $309.35 | 2022-2024 | Relistor |
| Collegium Pharmaceutical, INC. | $154.64 | 2023-2024 | Xtampza |
| Lilly USA, LLC | $63.35 | 2025 | Zepbound, Mounjaro |
| Hikma Pharmaceuticals USA | $46.87 | 2022 | |
| Valinor Pharma, LLC | $45.93 | 2023-2024 | Movantik |
| Grt US Holding, INC. | $45.02 | 2022 | |
| Protega Pharmaceutials INC | $43.62 | 2024 | Roxybond |
| Lundbeck LLC | $38.84 | 2024 | Vyepti |
| Idorsia Pharmaceuticals US INC | $22.92 | 2023 | Quviviq |
| Amneal Pharmaceuticals LLC | $21.50 | 2023 | Lyvispah |
| Kowa Pharmaceuticals America, INC. | $16.04 | 2023 | Seglentis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mirei Malave listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.